Latest Market Entry News

AnteoTech has formalised a strategic alliance with South Korea’s Xerabrid to co-develop and commercialise a breakthrough battery separator combining their proprietary technologies, targeting high-performance applications in eVTOL, EVs, and consumer electronics.

Medical Developments International (ASX:MVP) reported a 9% revenue increase to $42.6 million and a 566% jump in net profit to $0.6 million for FY26, driven by robust growth in its Pain Management segment and expanded paediatric approvals in Europe.

Dusk Group delivered record FY26 sales and underlying EBIT growth, driven by product rejuvenation and online momentum, while preparing for international expansion amid ACCC proceedings.

SkyCity Entertainment Group reported a 22% drop in underlying EBITDA for FY26, impacted by regulatory costs and carded play rollout, while progressing asset sales and preparing for New Zealand's online casino market.

Nodestream has engaged Waypoint Strategic Partners to provide hands-on leadership and operational support for its US market entry, marking a shift from assessment to active execution under its Plan Consilience defence strategy.

KTEK Aerosystems has obtained a key export licence from the Netherlands, enabling it to ship components to its US facility for assembly and delivery. This milestone solidifies the company’s trans-Atlantic supply chain and supports its targeted September delivery restart.

Premier Investments trims FY26 Premier Retail EBIT forecast to $176 million, citing tough trading conditions and announces exit from UK Peter Alexander stores while focusing on Australian growth and loyalty programs.

ReNerve Limited has gained marketing approval for its flagship NervAlign Nerve Cuff in India, marking a critical milestone in its global expansion and enabling commercial rollout in one of the world's largest nerve repair markets.

AdAlta’s lead CAR-T therapy EW-001 continues to demonstrate encouraging survival and response rates in its mesothelioma study, with all patients alive at the latest follow-up and stronger outcomes at higher doses supporting plans for an Australian Phase 1 trial.

ReNerve has secured marketing approval for its NervAlign® Nerve Cuff in the Philippines, tapping into a major Southeast Asian market with significant nerve injury demand.

Clarity Pharmaceuticals has presented compelling clinical evidence that its investigational 64Cu-SAR-bisPSMA diagnostic and 67Cu-SAR-bisPSMA therapeutic candidates outperform current standards in prostate cancer care, positioning the company for regulatory and commercial milestones.

Acrux Limited spotlighted its Female Testosterone Metered Dose Transdermal System (MDTS) at the Bioshares Biotech Summit, revealing positive Phase II data and outlining a clear regulatory and commercial roadmap targeting Hypoactive Sexual Desire Disorder (HSDD) in women.